Bluejay Diagnostics (BJDX) Director Donald R. Chase Receives 100,000-Share Option Award

What Happened
Donald R. Chase, a director of Bluejay Diagnostics, was granted an award of 100,000 derivative securities on 2026-08-17. The grant is reported as having a $0 cash price at issuance (i.e., no purchase price paid). The award represents stock options that are currently out-of-the-money and will vest and become exercisable at $2.075 per share on the first anniversary of the grant date, but only if the U.S. Food and Drug Administration grants clearance or approval for Bluejay’s Symphony IL-6 point-of-care testing device.

Key Details

• Transaction date: 2026-08-17; Filing date: 2026-08-18 (filed the next day).
• Transaction type: Award/Grant of derivative securities (reported as A). Reported acquisition amount: 100,000 units at $0.00.
• Exercise/strike price and vesting: Options exercisable at $2.075 per share after one year, contingent on FDA clearance/approval (see footnote).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Timeliness: Filing appears timely (filed one day after the transaction). No 10b5-1 plan or tax-withholding details disclosed.

Context
This was an option award (compensation), not an open-market purchase or sale, so it does not represent an immediate cash investment or monetization by the insider. The options are conditional (both time-based vesting and regulatory-condition based), meaning they only become exercisable if Bluejay obtains FDA clearance/approval for its Symphony IL-6 device and one year passes. For retail investors, option grants to insiders are common as compensation; they signal potential future alignment with shareholder value but do not necessarily reflect immediate insider buying or selling.